The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients With Stable Coronary Heart Disease or Coronary Heart Disease Risk Equivalent. The Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

  1. Mohler III, E.R.
  2. Ballantyne, C.M.
  3. Davidson, M.H.
  4. Hanefeld, M.
  5. Ruilope, L.M.
  6. Johnson, J.L.
  7. Zalewski, A.
Aldizkaria:
Journal of the American College of Cardiology

ISSN: 0735-1097

Argitalpen urtea: 2008

Alea: 51

Zenbakia: 17

Orrialdeak: 1632-1641

Mota: Artikulua

DOI: 10.1016/J.JACC.2007.11.079 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus